We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug Industry Daily: Subscribe Now!
Email
Tweet

Drug Industry Daily: Subscribe Now!

Subscribe Now

Drug Industry Daily 

U.S. and international regulations and guidances… warning letters and enforcement trends… drug approvals and business development… lawsuits and court decisions… intellectual property and patent issues…

If you had access to the ultimate insider — someone with an ear to the ground at FDA, FTC, HHS, EU and other key agencies and decision-making bodies affecting the pharmaceutical industry around the world — how might you use this intelligence to help your business?

Subscribe to Drug Industry Daily (DID). It is the next best thing, providing you with daily electronic updates and insights you can use to increase your competitive edge.

DID is the premier resource for pharmaceutical executives to obtain accurate insider information on the daily activities of the agencies most directly affecting their businesses:

  • Use DID’s information on FDA’s pharmaceutical regulatory actions and policies to stay current with the latest industry trends and developments, ensuring you are using the most efficient and cost-effective processes.
  • Rely on DID’s insights to impact your decisions and provide context for how to improve processes and maintain compliance, ultimately saving time and money.
  • Use DID’s monitoring of the latest enforcement trends — including Form 483 inspection reports — to ensure your organization remains in compliance rather than losing time and money by having to create and implement corrective action plans.

DID is the secret information weapon of top pharmaceutical executives — Boehringer Ingelheim, Johnson & Johnson, GSK, Novartis, Bayer, Pfizer… —giving them a competitive edge with actionable intelligence.

Ensure you’re in-the-know today. Arm yourself with the most up-to-date news on top issues, including:

  • Patent exclusivity
  • Market globalization enforcement
  • EU pharmacovigilance
  • New inspection trends
  • Advertising practices
  • Warning letters
  • Recalls
  • Approvals
  • And much more…

Get each issue of DID with links to documents that saves you time. Links include draft and final guidances, 483s and warning letters, proposed rules, closeout letters, and the full text of proposed legislation and GAO reports.

You’ll have each issue covering a specific topic, with a helpful recap at the end of each week:

Monday

Tuesday

Wednesday

Thursday

Friday

Regulatory Update

People on the Move

Legislative Update

FDA Meeting Planner

Week in Review

Start your one-year subscription (250 issues) DID for only $1,695.

We’re confident the value DID provides you will pay for itself many times over. If you disagree, there’s our No-Risk, 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Drug Industry Daily, you may cancel your subscription and receive a full refund. No questions asked.

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing